

1 **Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: A randomized, double-**
2 **blind, placebo-controlled trial**
3

4
5
6 Sven R. Andresen^{a,*}, Jette Bing^b, Rikke M. Hansen^a, Fin Biering-Sørensen^b, Inger L. Johannesen^a, Ellen
7 Merete Hagen^{a,c,d}, Andrew S.C Rice^e, Jørgen F. Nielsen^f, Flemming W. Bach^g, Nanna B. Finnerup^h
8
9

10
11 ^a*Spinal Cord Injury Centre of Western Denmark, Viborg, Denmark*

12 ^b*Clinic for Spinal Cord Injuries, Rigshospitalet, University of Copenhagen, Denmark*

13 ^c*Department of Clinical Medicine, University of Bergen, Norway*

14 ^d*The Autonomic Unit, National Hospital for Neurology and Neurosurgery, Queen Square, University College*
15 *London, UK*

16 ^e*Pain Research, Department of Surgery and Cancer, Imperial College, London, UK*

17 ^f*Hammel Neurorehabilitation and Research Centre, Hammel, Denmark*

18 ^g*Department of Neurology, Aalborg University Hospital, Denmark*

19 ^h*Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Denmark*
20
21

22
23
24
25
26
27
28
29 *Corresponding author:

30 Sven Robert Andresen, MD

31 Spinal Cord Injury Centre of Western Denmark, Neurological Department

32 Regional Hospital of Viborg, Heibergs Allé 4

33 DK-8800 Viborg, Denmark

34 Tel: +45 7844 61 56 or +45 78 44 61 50; fax: +45 78 44 61 59.

35 E-mail address: sven.robert.andresen@midt.rm.dk
36
37

38
39
40
41
42
43 Article type: Clinical Science research report
44
45

46
47 Number of pages: 28 (17 text including references, 6 tables and 2 figures)

48 Number of tables: 2

49 Number of figures: 2

50
51
52 Supplementary material: 1
53
54
55

56 **Summary:** This randomized controlled trial found no effect of ultramicronized palmitoylethanolamide as
57 add-on-therapy on neuropathic pain after spinal cord injury.
58
59
60
61
62
63
64
65

1 **Abstract**

2 Neuropathic pain and spasticity after spinal cord injury (SCI) represent significant problems.

3
4 Palmitoylethanolamide (PEA), a fatty acid amide that is produced in many cells in the body, is thought to
5
6
7 potentiate the action of endocannabinoids and to reduce pain and inflammation. This randomized, double-
8
9
10 blind, placebo-controlled, parallel multicenter study was performed to investigate the effect of
11
12 ultramicronized PEA (PEA-um) as add-on therapy on neuropathic pain in individuals with SCI. A pain diary
13
14 was completed and questionnaires were completed before and after the 12-week treatment with either
15
16 placebo or PEA-um. The primary outcome measure was the change in mean neuropathic pain intensity
17
18 from the 1-week baseline period to the last week of treatment measured on a numeric rating scale ranging
19
20 from 0 to 10. The primary efficacy analysis was the intention to treat (baseline observation carried
21
22 forward). Secondary outcomes included a per protocol analysis and effects on spasticity, evoked pain, sleep
23
24 problems, anxiety, depression, and global impression of change. We randomized 73 individuals with
25
26 neuropathic pain due to SCI, of which 5 had a major protocol violation, and thus 68 were included in the
27
28 primary analysis. There was no difference in mean pain intensity between PEA-um and placebo treatment
29
30 ($P = 0.46$, mean reductions in pain scores 0.4 (-0.1 to 0.9) vs 0.7 (0.2 to 1.2); difference of means 0.3 (-0.4 to
31
32 0.9)). There was also no effect of PEA-um as add-on therapy on spasticity, insomnia, or psychological
33
34 functioning. PEA was not associated with more adverse effects than placebo.
35
36
37
38
39
40
41
42

43 **Keywords**

44
45 Neuropathic pain, Spasticity, Spinal cord injury, PEA, ultramicronized Palmitoylethanolamide, Randomized
46
47 Controlled Trial
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **1. Introduction**

2
3 Neuropathic pain and spasticity due to spinal cord injury (SCI) remain significant problems [28,34].

4
5 About 50-60% develop chronic neuropathic pain and 70% spasticity after SCI [4,10,34]. Neuropathic pain is
6
7 pain due to a lesion or disease of the somatosensory nervous system, and neuropathic SCI pain is divided
8
9 into "at-level" and "below-level" pain [5]. Spasticity is here defined as a "disordered sensory-motor control,
10
11 resulting from an upper motor neuron lesion, presenting as intermittent or sustained involuntary activation
12
13 of muscles", including hyperreflexia, increase in muscle tone, spasms, and clonus [28,33].
14
15

16
17 The usefulness of cannabinoids in the treatment of neuropathic pain is unclear and their use limited by
18
19 side effects and concerns about long term risks [9,22]. Therefore, efforts concentrate about the
20
21 development of cannabinoids with a better therapeutic index [22,23,42]. Palmitoylethanolamide (PEA) is
22
23 an endogenous fatty acid amide that is suggested to potentiate endocannabinoids and to have effect on
24
25 neuropathic pain and spasticity [1,15,16,19,21,25,31,35,36]. PEA prolongs and potentiates the action of
26
27 endocannabinoids through an inhibition of fatty acid amide hydrolase [40]. PEA has also been suggested to
28
29 reduce inflammation and to have neuroprotective mechanisms [13,17,36,39]. In several neuropathic pain
30
31 models in rats, palmitoylethanolamide (L-29), an analogue - of PEA, has effects suggestive of analgesia [30,40].
32
33 Micronization and ultramicrosonization have been used to reduce the large particle PEA to micron- and sub-
34
35 micron-sized crystals to enhance dissolution and reduce variability of absorption [18]. Case reports and
36
37 open-label studies suggest an effect of ultramicrosonized PEA (PEA-um) on neuropathic pain, including central
38
39 pain [7,12,16,32]. Recent systematic reviews in neuropathic pain and PEA [9,16,36] have only identified 2
40
41 randomized placebo-controlled trials, both showing efficacy of micronized PEA (PEA-m) in sciatic pain
42
43 [6,11]. PEA-um is registered as food for special purposes (FSMP) by the Italian Ministry of Health. PEA-um
44
45 is not labeled for use in neuropathic pain.
46
47
48
49
50
51
52

53 Our randomized clinical trial examined the effect of PEA-um as add-on therapy on neuropathic pain
54
55 following SCI and furthermore evaluated its effect on spasticity and psychological functions.
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1. Methods

2.1. Design

This was an investigator-initiated, randomized, double-blind, placebo-controlled, parallel multicenter study investigating sublingual PEA-um microgranules 600 mg in patients with neuropathic pain after SCI.

2.2. Study population

Inclusion criteria were: 18 years or older and having sustained a traumatic or non-traumatic SCI including cauda equine lesions. The SCI should be at least 6 months old and patients should have at- and/or below-level SCI neuropathic pain [5] that had lasted for at least 3 months with an average pain intensity of at least 4 and not above 9 on a 0-10 point numeric rating scale (NRS) , where 0 is “no pain” and 10 is “the worst pain you could imagine”, during a 7-day baseline period [8]. Patients should have definite neuropathic pain, which requires a pain distribution compatible with the SCI, ie. at- or below-injury level, sensory signs in the same neuroanatomically plausible distribution, and a diagnostic test, typical a MRI, confirming the SCI [38], and the pain should have no primary relation to movement. Musculoskeletal or other nociceptive pain that could explain the pain should be excluded or considered unlikely. Exclusion criteria included known concomitant severe cerebral damage, terminal illness, planned surgery, alcohol or substance abuse, hypersensitivity to PEA-um or excipients, psychiatric disease except reactive depression, pregnancy, and lactation, and if they could not differentiate their neuropathic SCI pain from other types of pain. All women of childbearing age had to use sufficient contraceptives (birth control pills, intrauterine device or sterilization). Patients were allowed to continue concomitant treatment with spasmolytics and drugs for pain in a constant and unchanged dose during the study. If possible, patients were tapered off their pain medication, however none of the patients accepted to be reduced in dose or tapered off. The study was approved by the Ethical Committee of the Central Denmark Region (no. 1-10-72-77-13) and the Danish Data Protection Agency, Copenhagen, Denmark (no. 1-16-02-106-13). The study was conducted in

1 accordance with the Declaration of Helsinki and was registered at ClinicalTrials.gov (NCT01851499). All
2
3 patients gave informed written consent.
4
5
6
7

8 *2.3. Medication*

9

10
11 The study drug was a sublingual product based on ultramicrosized PEA (Normast®). PEA-um 600 mg or
12
13 identical placebo was given sublingually twice daily with approximately 12 hours between doses for a
14
15 period of 12 weeks. Both patients and investigators were blinded, and assignment to treatment was
16
17 randomized via a computer-generated randomization list with a homogeneous block size of 4 done by
18
19 Epitech Group SpA, and patients were allocated consecutively.
20
21
22

23 Assessment of compliance: At the end of the treatment period, the patients returned the remaining
24
25 sachets, and the amount relative to the daily recordings in the diary of consumption of Normast was
26
27 recorded in a case report form.
28
29
30
31

32 *2.4. Procedure*

33
34
35

36 The patients were recruited from May 2013 to December 2014. Patients came for 3 visits. After the first
37
38 visit, the patients underwent a baseline week, after which they were randomized to Normast or placebo for
39
40 12 weeks. Throughout the study (13 weeks), the patients completed a pain diary every evening and
41
42 recorded their average pain, spasticity, and sleep disturbance experienced in the preceding 24 hours and
43
44 their use of rescue medication. At visit 1, the patients' history, including pain and spasticity symptoms, was
45
46 collected, and general and neurological examinations were made. SCI was classified according to the
47
48 International Standards for Neurological Classification of SCI [20,24], and patients completed the
49
50 International Spinal Cord Injury Pain Basic Data Set [41].
51
52
53
54
55
56

57 *2.5. Primary outcome*

58
59
60
61
62
63
64
65

1 Neuropathic SCI pain was assessed with the NRS (0-10). The predefined primary outcome was the
2
3 difference in the mean value of the patient's daily ratings of average pain intensity in the baseline week and
4
5 the last week of the treatment period.
6

7 8 9 10 11 *2.6. Secondary outcomes*

12 Average neuropathic pain intensity scores in the treatment weeks (weeks 2-12) and the daily ratings of
13
14 spasticity and sleep disturbance in the last week of the treatment period were secondary outcome
15
16 measures. Other secondary outcomes were the intensity of muscle stiffness and spasms rated on a 0-10
17
18 NRS, use of rescue medication, neuropathic pain descriptors, impact of the neuropathic pain, health-
19
20 related quality of life using the Pain Survey (S-TOPS) [14] , evoked pain, spasticity assessed using the
21
22 Modified Tardieu Scale (MTS) [37] , the Patient Global Impression of Change (PGIC), pain relief, the number
23
24 needed to treat (NNT), the Insomnia Severity Index (ISI) [26] , the Major Depression Inventory (MDI)
25
26 [2,3,27], and the Generalized Anxiety Disorder Assessment (GAD-10). For further details on the methods,
27
28 please see supplementary material.
29
30
31
32
33
34
35
36

37 *2.7. Other outcomes*

38 Adverse effects were assessed by open-ended questions, and blindness of both the investigator and the
39
40 participants was assessed by asking which treatment they believed they had received (active or placebo)
41
42 and asking them about their reason for this belief.
43
44
45
46
47
48

49 *2.8. Statistical analysis*

50 Our sample size calculation predetermined that 66 patients should complete the study to be able to find
51
52 a difference in pain score of at least 1.5 point on an NRS (0-10) with an estimated standard deviation (SD) of
53
54 2.0 (85% strength, $\alpha = 0.05$). The primary efficacy variable (change in average weekly pain score from
55
56 baseline to last week) and secondary efficacy variables were analyzed by t-test or Mann-Whitney test,
57
58
59
60
61
62
63
64
65

1 where applicable. An analysis using ANCOVA with baseline pain intensity, number of rescue tablets, gender,
2
3 age, and treatment as covariates was also performed.
4

5
6 The main analysis was on the intention-to-treat (ITT) population, including all patients taking the first
7
8 dose. Five patients were randomized despite an average pain intensity of < 4 or > 9 and were not included
9
10 in the primary modified ITT analysis. Patients were asked to complete the pain diaries despite their
11
12 withdrawal from trial medication. In the absence of data from pain diaries and secondary outcomes, "the
13
14 baseline observation carried forward" (BOCF) method was used. In addition, the "per protocol" (PP)
15
16 population was analyzed, which was defined as the number of individuals who had been treated with at
17
18 least 600 mg of ultramicrosized PEA twice a day for 8 weeks and who had consumed 70-110% of the
19
20 expected dose. Statistical analysis was performed with STATA release 12 (StataCorp, College Station, TX,
21
22 USA).
23
24
25
26
27
28

29 **2. Results**

30 *3.1. Patients*

31
32
33
34
35
36 Patients were recruited from May 2013 to December 2014 and last follow-up visit was in April 2015. A
37
38 total of 119 patients were assessed for eligibility and 73 were randomized for treatment, see consort flow
39
40 diagram (Fig. 1). Of the 73 patients randomized, 5 patients had major protocol violation (did not meet the
41
42 criteria of baseline pain intensity of $4 \leq \text{NRS} \leq 9$) and were thus not included in the primary modified ITT
43
44 analysis; however, they were included in the safety analysis and in a secondary ITT analysis.
45
46

47
48 Demographics and patient baseline characteristics included in the safety and secondary ITT analyses are
49
50 displayed in Table 1. Of the 73 patients, 36 were randomized to PEA-um and 37 to placebo. Average age
51
52 was 56.3 years (SD: 11.6), average time since injury was 10.3 (SD: 11.7), and average pain intensity during
53
54 baseline was 6.4 (SD: 1.4) (NRS 0-10).
55
56
57
58
59
60
61
62
63
64
65

3.2. Primary outcome

There was no statistically significant difference between PEA-um and placebo on the primary outcome in the ITT (n = 68) population (Δ mean: 0.3, 95% CI: -0.4 to 0.9, $P = 0.46$) (Table 2, Fig. 2). There was also no difference when using ANCOVA with the covariates (gender, age, baseline mean pain intensity, use of rescue medication, and treatments) (modified ITT without protocol violations: n = 68, $P = 0.82$). T-test (Table 2) and ANCOVA analyses also showed no difference between groups when analyses were done for the secondary ITT (including the 5 patients with major protocol violations) (n = 73) and the PP (n = 58) populations.

3.3. Secondary outcomes

The patient group treated with PEA-um had a larger consumption of rescue medication at baseline and had a significantly larger reduction in the use of rescue medication than those treated with placebo; in the latter group baseline use was lower and increased during the observation period (Δ mean: -2.2, 95% CI: -4.0 to -0.3, $P = 0.02$). Patients treated with PEA-um had an increase in self-reported intensity of spasticity from the pain diary recordings compared to a decrease in patients treated with placebo (Δ mean: 1.0, 95% CI: 0.2 to 1.9, $P = 0.013$), but there was no difference in other self-reported or laboratory spasticity outcomes (Supplementary Table 1). For all other secondary outcomes there were no statistically significant differences between treatments (Supplementary material).

3.4. Assessment of blindness

Of those allocated to PEA-um, 16% of patients identified the correct treatment and stated that it was due to pain relief, whereas 84% thought they had received placebo due to lack of effect. Of those who received placebo, 81% identified the correct treatment due to lack of pain relief, whereas 19% thought they had received active treatment due to effect of the treatment. No patient stated that the reason for their

1 choice was adverse effects. We saw no significant difference between the treatment groups ($P = 0.78$),
2
3 suggesting that blinding was preserved.
4
5
6
7

8 *3.5. Compliance*

9

10 For patients in the primary modified ITT analysis who were not lost to follow up ($n=63$), the mean daily
11 dose throughout the treatment period was 1135.4 mg (SD: 122.2) for PEA-um and 1165.1 mg (SD: 76.7) for
12 placebo, and mean treatment length was 11.6 weeks (SD: 1.4) for PEA-um and 11.3 weeks (SD: 2.1) for
13 placebo. 26 of 31 patients treated with PEA-um and 27 of 32 patients treated with placebo completed 12
14 weeks of treatment. Mean compliance was 94.6 % (SD: 10.2) for PEA-um and 97.1 % (SD: 6.4) for placebo.
15
16
17
18
19
20
21
22
23

24 *3.6. Adverse events*

25

26
27 Seven patients reported adverse events, of which 5 were serious adverse events. One patient treated
28 with PEA-um committed suicide, which, after careful investigation, was not considered to be related to the
29 study drug. No other patients dropped out of the study because of adverse events. Other serious adverse
30 events were urinary tract infection, paralytic ileus, cholecystolithiasis, and erysipelas causing hospitalization
31 in 3 patients treated with PEA-um and 1 treated with placebo. In addition, 1 patient treated with PEA-um
32 had fungus infection, and 1 treated with placebo experienced blurred vision.
33
34
35
36
37
38
39
40
41
42

43 **3. Discussion**

44

45 In this randomized , double-blind, placebo-controlled study, 1200 mg ultramicronized PEA (600mg BID)
46 as add-on therapy failed to show an effect on SCI neuropathic pain. In addition, PEA-um add-on had no
47 effect on spasticity and other secondary outcomes. However, the patient group treated with PEA-um add-
48 on had a significantly larger reduction in the use of rescue medication (paracetamol) than those treated
49 with placebo. A lower consumption of concomitant medication during treatment with PEA-m has been
50 shown in a study of individuals with lumbar radicular pain [6]. Including the use of rescue medication in the
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 ANCOVA, we still found no effect of PEA-um as add-on therapy on the primary outcome; consistent with
2
3 the fact that there is no evidence that paracetamol has any effect on neuropathic pain. We did not correct
4
5 for multiple comparisons for the secondary outcomes, and this may likely be a chance finding, although we
6
7 cannot exclude that PEA-um had an effect on other types of pain for which the patients took paracetamol.
8
9 Placebo was more effective than PEA as add-on therapy on spasticity according to the pain diary, but this
10
11 was not supported by other spasticity outcomes.
12
13

14
15 This study is the first randomized, double-blind, placebo-controlled trial examining PEA-um as add-on
16
17 therapy in central pain. The 12-week treatment period and the dosage of 600 mg twice daily were equal to
18
19 or higher in our study compared with earlier studies [6,11,12,16], so the lack of effect is not likely to be
20
21 explained by a suboptimal dose, although we cannot exclude that a higher dose is needed to relieve central
22
23 SCI pain. It is also not likely to be explained by a floor-effect, because the average pain intensity was 6.4 on
24
25 a 0-10 NRS. There are limited pharmacokinetic data on PEA-um, and limited penetration to the
26
27 cerebrospinal fluid could be an explanation for the lack of efficacy. Our study included patients with
28
29 different causes and levels of SCI, which could impact the outcome, and patients with concomitant
30
31 medication which could have an impact on the effect of PEA-um, and it is likely that we included some
32
33 patients that are refractory to pain treatment, which could also contribute to the lack of effect, also
34
35 considering that more patients randomized to PEA were treated with concomitant medication. Finally it is
36
37 possible, that the effect seen in experimental studies is driven mainly by reduced inflammation and
38
39 neuroprotective mechanisms [13,29] and that treating spinal cord-injured individuals with PEA-um in early
40
41 stages and before neuropathic pain and spasticity develop, may be beneficial.
42
43
44
45
46
47

48 Our study supports that ultramicrosized PEA has good safety and tolerability profiles. Only 1 patient
49
50 stopped treatment due to an adverse event, which was considered unrelated to the study drug.
51
52

53 In conclusion, this study showed no effect of PEA-um as add-on therapy on neuropathic pain following
54
55 SCI and any of the secondary outcomes, including spasticity, with exception of rescue drugs use which was
56
57 decreased in the PEA-um treated group.
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Funding

The study was supported by Region Midtjyllands Sundhedsvidenskabelige Forskningsfond, Hospitalenheden Midt forskningspulje and The Danish Society of Polio and Accident Victims (PTU). Epitech Group SLR provided the study drug and placebo and performed the randomization. The funding source (Epitech Group SLR) had the possibility to comment on the design and reporting of the study, but had no role in the collection, analysis, and interpretation of the data. All authors had full access to all data and the corresponding author had the final responsibility for the decision to submit for publication.

Conflict of interest statement

The authors have no conflicts of interest to declare within the submitted work. NBF reports honoraria from Pfizer and Grünenthal and grants from IMI Europain (EU/EFPIA) outside the submitted work. ASCR is a member of the Scientific Advisory Board, has received research funding from and holds share options in Spinifex. ASCR has undertaken paid consultancy work via Imperial College Consultants which in the last 3 years has included work for Neusentis, Spinifex, Abide, Orion, Merck, Astellas, Medivir, Asahi Kasei, Aquilas, Relmada and Mitsubishi. Within the last 3 years ASCR’s laboratory has received grants from Pfizer and Astellas and IMI Europain (EU/EFPIA). ASCR has a patent - Rice A.S.C., Vandevoorde S. and Lambert D.M Methods using N-(2-propenyl)hexadecanamide and related amides to relieve pain. WO 2005/079771. FWB has received investigator fees from Pfizer and Grunenthal. RMH cooperates with Bioarctic,. SRA, JB, EMH and FB-S declare no conflict of interests.

Acknowledgements

1 We thank Anne Grethe Rasmussen and Henriette Rask, Clinic for Spinal Cord Injury at Rigshospitalet, for
2
3 their assistance in data collection and Susanne Doessing, Spinal Cord Injury Centre of Western Denmark, for
4
5 recruitment of SCI individuals.
6
7
8
9
10

11 **References**

- 12
- 13 [1] Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F,
14 Bisogno T, Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. *FASEB J*
15 2001;15:300–2.
16
17 [2] Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W. The sensitivity and specificity of the
18 Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. *J*
19 *Affect Disord* 2001;66:159–64.
20
21 [3] Bech P, Wermuth L. Applicability and validity of the Major Depression Inventory in patients with
22 Parkinson’s disease. *Nord J Psychiatry* 2015;52:305–309.
23
24 [4] Biering-Sorensen F, Nielsen JB, Klinge K, Biering-Sørensen F. Spasticity-assessment: a review. *Spinal*
25 *Cord* 2006;44:708–722.
26
27 [5] Bryce TN, Biering-Sørensen F, Finnerup NB, Cardenas DD, Defrin R, Lundeberg T, Norrbrink C,
28 Richards JS, Siddall P, Stripling T, Treede R-D, Waxman SG, Widerström-Noga E, Yezierski RP, Dijkers
29 M. International spinal cord injury pain classification: part I. Background and description. *Spinal Cord*
30 2012;50:413–7.
31
32 [6] Canteri L, Petrosino S GG. Reducción del consumo de antiinflamatorios y analgésicos en el
33 tratamiento del dolor neuropático crónico en pacientes afectados por lumbociatalgia de tipo
34 compresivo y en tratamiento con Normast® 300 mg. *Dolol* 2010;25:227–234.
35
36 [7] Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized
37 palmitoylethanolamide in peripheral neuropathic pain. *Pain Res Treat* 2014;2014:854560.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [8] Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN,
2 Rappaport BA, Rowbotham MC, Backonja M-M, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan
3 P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman
4 JD, McDermott MP, Munera C, Porter L, Rauschkolb C, Rice ASC, Sampaio C, Skljarevski V,
5 Somerville K, Stacey BR, Steigerwald I, Tobias J, Trentacosti AM, Wasan AD, Wells GA, Williams J,
6 Witter J, Ziegler D. Considerations for improving assay sensitivity in chronic pain clinical trials:
7 IMMPACT recommendations. *Pain* 2012;153:1148–58.
8
9
10
11
12
13
14
15
16
17 [9] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson
18 P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P,
19 Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and
20 meta-analysis. *Lancet Neurol* 2015;14:162–173.
21
22
23
24
25
26
27 [10] Finnerup NB, Norrbrink C, Trok K, Piehl F, Johannesen IL, Sørensen JC, Jensen TS, Werhagen L.
28 Phenotypes and predictors of pain following traumatic spinal cord injury: a prospective study. *J Pain*
29 2014;15:40–8.
30
31
32
33
34 [11] G. Guida, A. de Fabiani, F. Lanaia, A. Alexandre, G.M. Vassallo, L. Cantieri, M. de Martino, M. Rogai
35 SP. La palmitoiletanolamida (Normast®) en el dolor neuropático crónico por lumbociatalgia de tipo
36 compresivo: estudio clínico multicéntrico. *Dolol* 2010;25:35–42.
37
38
39
40
41 [12] Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the
42 treatment of chronic pain caused by different etiopathogenesis. *Pain Med* 2012;13:1121–30.
43
44
45
46 [13] Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea
47 S. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal
48 cord injury. *J Pharmacol Exp Ther* 2008;326:12–23.
49
50
51
52
53 [14] Haroutiunian S, Donaldson G, Yu J, Lipman AG. Development and validation of shortened,
54 restructured Treatment Outcomes in Pain Survey instrument (the S-TOPS) for assessment of
55 individual pain patients' health-related quality of life. *Pain* 2012;153:1593–601.
56
57
58
59
60
61
62
63
64
65

- 1 [15] Helyes Z, Németh J, Thán M, Bölcskei K, Pintér E, Szolcsányi J. Inhibitory effect of anandamide on
2
3 resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat.
4
5 Life Sci 2003;73:2345–53.
6
7
- 8 [16] Hesselink J. New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. Open
9
10 Pain J 2012;5:12–23.
11
12
- 13 [17] Hesselink JMK. Evolution in pharmacologic thinking around the natural analgesic
14
15 palmitoylethanolamide: from nonspecific resistance to PPAR- α agonist and effective nutraceutical. J
16
17 Pain Res 2013;6:625–34.
18
19
- 20 [18] Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E, Cuzzocrea S.
21
22 Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to
23
24 nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation
25
26 2014;11:136.
27
28
- 29 [19] Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid
30
31 anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic
32
33 inflammatory pain. Pain 1998;76:189–99.
34
35
- 36 [20] Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, Johansen M, Jones L,
37
38 Krassioukov A, Mulcahey MJ, Schmidt-Read M, Waring W. International standards for neurological
39
40 classification of spinal cord injury (revised 2011). J Spinal Cord Med 2011;34:535–46.
41
42
- 43 [21] Lambert DM, Vandevorde S, Jonsson K-O, Fowler CJ. The palmitoylethanolamide family: a new class
44
45 of anti-inflammatory agents? Curr Med Chem 2002;9:663–74.
46
47
- 48 [22] Lever IJ, Rice ASC. Cannabinoids and pain. Handb Exp Pharmacol 2007:265–306.
49
50
- 51 [23] Maione S, Costa B, Di Marzo V. Endocannabinoids: a unique opportunity to develop multitarget
52
53 analgesics. Pain 2013;154 Suppl:S87–93.
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [24] Marino RJ, Barros T, Biering-Sorensen F, Burns SP, Donovan WH, Graves DE, Haak M, Hudson LM,
2
3 Priebe MM. International standards for neurological classification of spinal cord injury. *J Spinal Cord*
4
5 *Med* 2003;26 Suppl 1:S50–6.
6
7
8 [25] Mattace Raso G, Russo R, Calignano A, Meli R. Palmitoylethanolamide in CNS health and disease.
9
10 *Pharmacol Res* 2014;86:32–41.
11
12 [26] Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to
13
14 detect insomnia cases and evaluate treatment response. *Sleep* 2011;34:601–8.
15
16
17 [27] Olsen LR, Jensen D V, Noerholm V, Martiny K, Bech P. The internal and external validity of the Major
18
19 Depression Inventory in measuring severity of depressive states. *Psychol Med* 2003;33:351–6.
20
21
22 [28] Pandyan AD, Gregoric M, Barnes MP, Wood D, Van Wijck F, Burridge J, Hermens H, Johnson GR.
23
24 Spasticity: clinical perceptions, neurological realities and meaningful measurement. *Disabil Rehabil*
25
26 2005;27:2–6.
27
28
29 [29] Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E. A new co-ultramicro-
30
31 nized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord
32
33 injury. *J Neuroinflammation* 2013;10:91.
34
35
36 [30] Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V. Changes in spinal and
37
38 supraspinal endocannabinoid levels in neuropathic rats. *Neuropharmacology* 2007;52:415–22.
39
40
41 [31] Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related
42
43 cannabimimetic compounds in protection against tissue inflammation and pain: potential use in
44
45 companion animals. *Vet J* 2007;173:21–30.
46
47
48 [32] Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide
49
50 reduces the symptoms of neuropathic pain in diabetic patients. *Pain Res Treat* 2014;2014:849623.
51
52
53 [33] Sheean G. The pathophysiology of spasticity. *Eur J Neurol* 2002;9 Suppl 1:3–9; discussion 53–61.
54
55
56 [34] Siddall PJ, McClelland JM, Rutkowski SB, Cousins MJ. A longitudinal study of the prevalence and
57
58 characteristics of pain in the first 5 years following spinal cord injury. *Pain* 2003;103:249–257.
59
60
61
62
63
64
65

- 1 [35] Skaper SD, Facci L, Barbierato M, Zusso M, Bruschetta G, Impellizzeri D, Cuzzocrea S, Giusti P. N-
2
3 Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution. *Mol*
4
5 *Neurobiol* 2015;52:1034–1042.
6
7
- 8 [36] Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, Giusti P. Palmitoylethanolamide, a
9
10 naturally occurring disease-modifying agent in neuropathic pain. *Inflammopharmacology*
11
12 2014;22:79–94.
13
14
- 15 [37] Tardieu G, Shentoub G, Shentoub S, Delarue R. [Research on a technic for measurement of
16
17 spasticity]. *Rev Neurol (Paris)* 1954;91:143–4.
18
19
- 20 [38] Treede R-D, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R,
21
22 Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research
23
24 purposes. *Neurology* 2008;70:1630–5.
25
26
- 27 [39] Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. The nuclear receptor
28
29 peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of
30
31 palmitoylethanolamide. *Mol Pharmacol* 2005;67:15–9.
32
33
- 34 [40] Wallace VCJ, Segerdahl AR, Lambert DM, Vandevoorde S, Blackbeard J, Pheby T, Hasnie F, Rice ASC.
35
36 The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in
37
38 rodent models of neuropathy. *Br J Pharmacol* 2007;151:1117–28.
39
40
- 41 [41] Widerström-Noga E, Biering-Sørensen F, Bryce T, Cardenas DD, Finnerup NB, Jensen MP, Richards JS,
42
43 Siddall PJ. The international spinal cord injury pain basic data set. *Spinal Cord* 2008;46:818–23.
44
45
- 46 [42] Woodhams SG, Sagar DR, Burston JJ, Chapman V. The role of the endocannabinoid system in pain.
47
48 *Handb Exp Pharmacol* 2015;227:119–43.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 **Figure legends**

2
3 **Figure 1.** Study flow chart

4
5 *Personal reasons (e.g. too long study period, to many visits, lack of time, did not want to participate in a
6
7
8 trial)

9
10 **In addition to participants lost to follow-up

11
12 ***Did not meet criteria for randomization of average pain intensity in the baseline period of $4 \leq \text{NRS} \leq 9$

13
14
15 ****No protocol violation, treatment ≥ 8 weeks and $\geq 70\%$ intake of study medication

16
17
18 **Figure 2.** Time course of mean pain intensity during study

19
20
21 Mean pain intensity on a numeric rating scale (0-10) from baseline by week of treatment (last week of
22
23 treatment was week 12) for the Normast (●) and Placebo (○) population (baseline observation carried
24
25 forward imputation). Error bars are standard error of the mean. NRS=Numeric Rating Scale

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Summary:

This randomized controlled trial found no effect of ultramicrosized palmitoylethanolamide as add-on-therapy on neuropathic pain after spinal cord injury.

Figure 1




Figure 2. Time course of mean pain intensity during study

[Click here to download Figure Figure_2_mean_pain.TIF](#)




Table 1. Demographics and baseline characteristics

	PEA (n=36)	Placebo (n=37)	Total (n=73)
Age, years, mean (SD)	58.6 (11.3)	54.1 (11.7)	56.3 (11.6)
Gender, n (%)			
Male	22 (61)	32 (86)	54 (74)
Female	14 (39)	5 (14)	19 (26)
Weight, kg, mean (SD)	80.0 (15.8)	74.7 (14.2)	77.3 (15.1)
Time since injury, years, mean (SD)	9.4 (12.8)	11.1 (10.6)	10.3 (11.7)
Baseline score, NRS 0-10			
Pain score, mean (SD)	6.5 (1.4)	6.3 (1.5)	6.4 (1.4)
Spasticity score, mean (SD)	3.1 (2.8)	4.2 (2.7)	3.6 (2.8)
Sleep disturbance, mean (SD)	4.5 (2.7)	3.6 (2.2)	4 (2.5)
Level of neuropathic pain, n (%)			
At-level	9 (25)	7 (18)	16 (22)
At- and below-level	13 (36)	15 (41)	28 (38)
Below-level	14 (39)	15 (41)	29 (40)
Classification of neurological level, n (%)			
Tetraplegia	17 (47)	15 (41)	32 (44)
Paraplegia	19 (53)	22 (59)	41 (56)
ASIA Impairment Scale, n (%)			
A: Complete	13 (36)	11 (30)	24 (33)
B: Incomplete	0 (0)	3 (8)	3 (4)
C: Incomplete	5 (14)	10 (27)	15 (21)
D: Incomplete	18 (50)	13 (35)	31 (42)
Causality of spinal cord injury, n (%)			
Sports	1 (3)	4 (11)	5 (7)
Assault	0 (0)	1 (2)	1 (1)
Transport	14 (39)	7 (19)	21 (29)
Fall	8 (22)	11 (30)	19 (26)
Other traumatic cause	2 (6)	4 (11)	6 (8)
Non-traumatic spinal cord dysfunction	11 (30)	10 (27)	21 (29)
Patients on concomitant pain and spasticity medication, n (%)	35 (97)	29 (78)	64 (88)
TCA	4 (11)	4 (11)	8 (11)
Gabapentin	19 (53)	8 (22)	27 (37)
Pregabalin	9 (25)	12 (32)	21 (29)
Tramadol	5 (14)	5 (14)	10 (14)
Strong opioids	10 (28)	5 (14)	15 (21)
Carbamazepin or Lamotrigin	1 (3)	1 (3)	2 (3)
Paracetamol	20 (56)	9 (24)	29 (40)
NSAID	2 (6)	3 (8)	5 (7)
Baclofen	11 (31)	12 (32)	23 (31)
Tizanidin	0 (0)	1 (3)	1 (1)

PEA=Palmitoylethanolamide, NRS= Numeric rating scale, TCA=Tricyclic antidepressants

Table 2. Primary outcome

	Baseline	PEA LWT	Δ^c	Baseline	Placebo LWT	Δ^c	Δ mean (95% CI) ^d	P-value ^d
Intention-To-Treat:								
Pain intensity, NRS 0-10, n=68	6.7 (1.2)	6.3 (1.7)	0.4 (1.4)	6.2 (1.1)	5.5 (1.8)	0.7 (1.4)	0.3 (-0.4 to 0.9)	0.46
Pain intensity ^a , NRS 0-10, n=73	6.5 (1.4)	6.1 (1.8)	0.4 (1.3)	6.3 (1.5)	5.7 (2)	0.7 (1.4)	0.3 (-0.34 to 0.94)	0.36
Per-Protocol:								
Pain intensity ^b , NRS 0-10, n=58	6.7 (1.2)	6.2 (1.8)	0.5 (1.5)	6.2 (1.1)	5.6 (1.8)	0.7 (1.4)	0.2 (-0.6 to 0.9)	0.69

Values are presented as mean (SD).

^aWith protocol violations (did not meet criteria for randomization of average pain intensity in the baseline period of $4 \leq \text{NRS} \leq 9$).

^bTreatment ≥ 8 weeks and $\geq 70\%$ intake of study drug without protocol violations.

^cChange in mean pain intensity (NRS 0-10) (baseline - LWT). Positive values represent a reduction in pain intensity.

^dTreatment effect PEA versus Placebo. $\Delta\text{mean} = \Delta\text{Placebo} - \Delta\text{PEA}$. Positive value means larger reduction during placebo than PEA.

*Decrease during PEA compared to decrease during placebo.

PEA=Palmitoylethanolamide, LWT=Last Week of Treatment, NRS=Numeric Rating Scale